USP <797> — Lexicon of the Business of Modern Medicine™

Pharmacy & Compounding

USP <797>

13 min readLast reviewed: June 2025AJ Pakpour, Healthcare Practice Startup & Strategy Expert
USP 797sterile compoundingpharmacy standardscleanroombeyond use date

Definition

USP <797> (Pharmaceutical Compounding — Sterile Preparations) is the United States Pharmacopeia general chapter that establishes minimum quality standards for the compounding of sterile preparations, including cleanroom design, environmental monitoring, personnel training, and beyond use dating, applicable to all facilities that compound sterile preparations.

Comprehensive Definition

USP General Chapter <797>, "Pharmaceutical Compounding — Sterile Preparations," is published by the United States Pharmacopeia (USP) and establishes the minimum standards for the preparation of compounded sterile preparations (CSPs) in the United States. The chapter applies to all facilities that compound sterile preparations — including 503A compounding pharmacies, 503B outsourcing facilities, hospital pharmacies, clinic-based compounding operations, and any other setting where sterile preparations are compounded. Compliance with USP <797> is required by most state boards of pharmacy and is considered the standard of practice for sterile compounding.

The 2023 revision of USP <797>, which became official on November 1, 2023, substantially updated and tightened the standards from the previous 2008 version. The revision reorganized the chapter, clarified requirements that had been ambiguous in the prior version, and introduced new or more stringent requirements in several areas. Key changes in the 2023 revision include revised ISO classification requirements for cleanrooms, new requirements for segregated compounding areas (SCAs), updated beyond use dating (BUD) tables, revised environmental monitoring requirements, and new requirements for personnel training and competency assessment.

Cleanroom design is one of the most significant compliance requirements under USP <797>. The chapter requires that sterile preparations be compounded in ISO-classified cleanrooms — specifically, an ISO 5 primary engineering control (PEC) such as a laminar airflow workbench (LAFW) or biological safety cabinet (BSC), located within an ISO 7 buffer area, which is in turn accessed through an ISO 8 ante-area. The specific ISO classification requirements depend on the category of CSP being prepared and the BUD assigned. Facilities that cannot meet these cleanroom requirements may use a segregated compounding area (SCA) with an ISO 5 PEC, but are limited to shorter BUDs.

Beyond use dating (BUD) is the date or time after which a CSP may not be used. USP <797> establishes BUD limits based on the category of CSP (Category 1 or Category 2), the sterility risk level, and whether the preparation is stored at controlled room temperature, refrigerated, or frozen. Category 1 CSPs are those compounded in a facility that does not meet all USP <797> environmental requirements or that have not been tested for sterility and endotoxins; they have shorter BUDs. Category 2 CSPs are those compounded in a fully compliant facility with appropriate testing; they may have longer BUDs.

Environmental monitoring (EM) is a systematic program of sampling and testing the air and surfaces in the compounding environment to detect microbial contamination. USP <797> requires facilities to conduct viable air sampling, non-viable air particle counting, and surface sampling at defined frequencies and locations. EM results must be reviewed and acted upon, and facilities must have action levels and corrective action procedures for EM excursions.

Why It Matters

USP <797> compliance is not optional for any facility that compounds sterile preparations. State boards of pharmacy in most states have adopted USP <797> by reference or have enacted regulations that incorporate its requirements. Failure to comply with USP <797> can result in disciplinary action by the state board, including license suspension or revocation. For 503B outsourcing facilities, USP <797> compliance is also a component of CGMP compliance and is evaluated during FDA inspections.

Beyond regulatory compliance, USP <797> exists to protect patients. Contaminated sterile preparations can cause serious infections, including sepsis and meningitis. The 2012 fungal meningitis outbreak that killed 64 people was caused by contaminated sterile preparations from a compounding pharmacy that was not compliant with applicable quality standards. USP <797> is designed to prevent such tragedies by establishing minimum standards for the compounding environment, personnel practices, and quality testing.

For operators who work with compounding pharmacies that prepare sterile preparations — or who are considering establishing in-house sterile compounding capabilities — understanding USP <797> is essential. The 2023 revision significantly raised the bar for compliance, and many pharmacies that were compliant under the old standards are not compliant under the new ones. Operators must verify that their pharmacy partners are compliant with the current version of USP <797> and must understand what compliance looks like in practice.

Historical Background

USP <797> was first published in 2004, establishing the first comprehensive national standards for sterile compounding in the United States. Prior to USP <797>, sterile compounding was governed by a patchwork of state regulations and professional guidelines that varied significantly across jurisdictions and did not provide a consistent national standard.

The 2008 revision of USP <797> updated and expanded the chapter, introducing the concept of sterility risk levels (low, medium, and high) as the basis for BUD assignment and adding more detailed requirements for environmental monitoring and personnel training. The 2008 version remained in effect for 15 years and became the de facto national standard for sterile compounding.

The 2023 revision was the product of a lengthy revision process that began in 2015 and involved extensive public comment and expert review. The revision was driven by advances in compounding science, lessons learned from compounding-related patient harm events, and the need to align USP <797> with current best practices in sterile manufacturing. The 2023 revision replaced the sterility risk level framework with a category-based approach (Category 1 and Category 2) and introduced numerous new or revised requirements.

Federal Regulations

USP <797> is a standard published by the United States Pharmacopeia, a non-governmental standards-setting organization. It is not itself a federal regulation, but it is incorporated by reference into federal and state regulations in several ways.

For 503B outsourcing facilities, CGMP compliance under 21 CFR Parts 210 and 211 is required by Section 503B of the FD&C Act (21 U.S.C. § 353b). The FDA considers USP <797> compliance to be a component of CGMP compliance for sterile compounding operations and evaluates USP <797> compliance during inspections of 503B facilities.

For 503A compounding pharmacies, USP <797> compliance is required by most state boards of pharmacy, which have adopted USP <797> by reference or enacted regulations that incorporate its requirements. The FDA does not directly enforce USP <797> against 503A pharmacies, but may consider non-compliance as evidence that a pharmacy is not operating within the 503A exemption.

State Considerations

State boards of pharmacy are the primary enforcers of USP <797> for 503A compounding pharmacies. Most states have adopted USP <797> by reference or have enacted regulations that incorporate its requirements. However, the timing and completeness of state adoption of the 2023 revision varies. Some states have explicitly adopted the 2023 revision; others are still operating under the 2008 version or have not yet updated their regulations.

Operators should verify the current USP <797> adoption status in the states where their pharmacy partners are licensed. A pharmacy that is compliant with the 2008 version of USP <797> may not be compliant with the 2023 revision, and the state board may or may not be enforcing the new standards yet.

Several states — including California, New York, and Florida — have enacted sterile compounding regulations that go beyond USP <797> in certain areas. California, for example, has specific facility design requirements and inspection programs for sterile compounding pharmacies that are more stringent than the USP <797> baseline.

Common Mistakes

  • Assuming that a pharmacy that was USP <797> compliant under the 2008 version is compliant under the 2023 revision — the 2023 revision introduced significant new requirements that require facility upgrades and process changes.
  • Not verifying that a pharmacy partner has been inspected under the 2023 USP <797> standards and has addressed any deficiencies identified.
  • Confusing beyond use dating under USP <797> with expiration dating of commercially manufactured drugs — BUDs for compounded sterile preparations are generally much shorter than expiration dates for commercial products.
  • Attempting to establish in-house sterile compounding without understanding the full scope of USP <797> requirements — the cleanroom design, environmental monitoring, and personnel training requirements are substantial.
  • Not reviewing a pharmacy's environmental monitoring data and corrective action records before establishing a supply relationship for sterile preparations.
  • Failing to understand the difference between Category 1 and Category 2 CSPs and the implications for BUD and storage requirements.

Operator Insight

The 2023 USP <797> revision is the most significant change to sterile compounding standards in 15 years, and it has created real compliance challenges for many pharmacies. When I evaluate pharmacy partners for operators who use sterile compounded preparations, I ask specifically about the 2023 revision: has the pharmacy been inspected under the new standards, what were the findings, and what corrective actions have been taken? The cleanroom requirements under the 2023 revision are particularly demanding. The new standards require more rigorous ISO classification, more frequent environmental monitoring, and more comprehensive documentation of monitoring results and corrective actions. Pharmacies that were operating in older facilities may need significant capital investment to upgrade their cleanrooms to meet the new standards. For operators who are considering establishing in-house sterile compounding capabilities — for example, a clinic that wants to prepare IV infusions or sterile injectables on-site — I strongly recommend a thorough assessment of the USP <797> requirements before making any investment. The cost of building and operating a compliant sterile compounding facility is substantial, and the ongoing compliance burden is significant. For most clinic-based operations, sourcing sterile preparations from a compliant 503A or 503B pharmacy is a more practical and cost-effective approach.

— AJ Pakpour, Healthcare Practice Startup & Strategy Expert

In Practice

A 503A compounding pharmacy that specializes in hormone therapy preparations decides to expand its sterile compounding capabilities to offer injectable preparations. The pharmacy's compliance team conducts a gap assessment against the 2023 USP <797> standards and identifies several deficiencies: the existing cleanroom does not meet the new ISO classification requirements, the environmental monitoring program is not sufficiently comprehensive, and the personnel training and competency assessment program needs to be updated. The pharmacy develops a remediation plan, upgrades its cleanroom, implements a new environmental monitoring program, and updates its training program before beginning sterile compounding operations. A hospital pharmacy department conducts its annual USP <797> compliance assessment and identifies that its beyond use dating practices for Category 2 CSPs are not consistent with the 2023 revision. The pharmacy director convenes a task force to review and update the BUD policies, trains all compounding staff on the new policies, and implements a documentation system to ensure that BUDs are assigned correctly for each preparation.

Frequently Asked Questions

References

  1. 1.USP <797> Pharmaceutical Compounding — Sterile Preparations (2023)
  2. 2.FDA: Sterile Drug Products Produced by Aseptic Processing — CGMP
  3. 3.ASHP: Guidelines on Compounding Sterile Preparations
  4. 4.USP: Compounding Resources

Further Reading

Turn Knowledge Into Action

Apply what you just learned. Book a strategy session with AJ Pakpour — healthcare practice startup and strategy expert.

Book a Strategy Session